findmyKOL

Meenakshi Jolly, MD

Basic profile

Rush University

ORCIDNPI
RegionChicago, IL · MidwestSpecialtyRheumatologyFocusRheumatology/Immunology
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2023Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Meenakshi Jolly is a Rheumatology/Immunology physician affiliated with Rush University. OpenAlex indexes 197 publications with 7,660 citations (h-index 40).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
197publications

Distinct works indexed by OpenAlex, matched via ORCID.

7,660citations

Total citations across indexed works.

40h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1725 W Harrison St
Suite 1017
Chicago, IL 606123841

Telephone

312-942-6641

Registry record last updated 8 Jul 2007.

View the NPPES registry record

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    33.9%
    Opioid Agonist10.1%
    Tramadol Hcl100%
    Part D17 patients
    Gabapentinoids10%
    Gabapentin79%Pregabalin21%
    Part D<11 patients

    + 3 more classes in this area

  • Cancer & immunology

    32.1%
    TNF inhibitor11.3%
    Humira(Cf) Pen83%Enbrel Sureclick17%
    Part D<11 patients
    Folate Analog Metabolic Inhibitor4.6%
    Methotrexate100%
    Part D<11 patients

    + 6 more classes in this area

  • Antiparasitic

    14.7%
    Antimalarial14.7%
    Hydroxychloroquine Sulfate100%
    Part D24 patients
Where care is delivered (Part B)94.5% facility · 5.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”